Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phas…
Biotechnology
US, Irvine [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Tarsus Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2021 | -1.3200 | -0.573 | 0 | 49 | -26 | -16 | -26 | -1 | -27 | -1 | 8 | 102 |
| 2022 | -0.6700 | -2.363 | 57 | 25 | -13 | -69 | -13 | -1 | -12 | -1 | 25 | 53 |
| 2023 | -2.5200 | -4.791 | 25 | 9 | -62 | -135 | -59 | 0.45 | -62 | 0.47 | 44 | 20 |
| 2024 | -4.6200 | -3.242 | 17 | 174 | -135 | -95 | -131 | -8 | -143 | -8 | 108 | 362 |
| 2025 | - | -1.808 | - | 310 | - | -70 | - | -14 | - | -15 | - | 647 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |